Merck said it will buy Verona Pharma for $10 billion to bolster its lung-disease business and help replace the expected loss ...

The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.

If you’ve been brushing off persistent fatigue frequent headaches or unexplained weight changes your body might be telling ...

The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.

The CAAT governance board recommends transitioning from the COPD Assessment Test to the CAAT and using it for patients with ...

COPD, or chronic obstructive pulmonary disease, affects more than 30 million Americans, yet many have never heard of it. COPD ...

A grant from the Melissa Andrews Trust has funded a software update for the Pulmonary Function Test machine (PFT) at ...

Lung conditions, like asthma and chronic obstructive pulmonary disease, are more common in women than men. Stephanie Harris ...

Synchrony Medical announced that it received FDA 510 (k) clearance for its LibAirty airway clearance system.

Verona Pharma’s flagship drug last year became the first new maintenance treatment for chronic obstructive pulmonary disease ...

“The brain is the gatekeeper of longevity,” said Wyss-Coray. “If you’ve got an old brain, you have an increased likelihood of ...

Merck said the deal is valued at $107 per ADS, a 23% premium to Verona’s closing price yesterday.